{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-267487","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2026-06-11T20:05:16+00:00","discovered_at":"2026-06-11T20:06:19.293431+00:00","generated_at":"2026-06-11T20:11:59.794997+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Bolt Biotherapeutics reports 2026 annual meeting voting results","bullets":["At June 10, 2026 annual meeting, 877,358 of 1,921,567 outstanding shares represented.","Directors William P. Quinn and Jakob Dupont elected as Class II members for three-year terms.","Quinn: 349,358 for, 52,117 withheld; Dupont: 377,163 for, 24,312 withheld; 475,883 broker non-votes each.","Ratification of PricewaterhouseCoopers as auditor for 2026: 768,336 for, 107,471 against, 1,551 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-267487","json":"https://secwatch.observer/filing/0001193125-26-267487.json","markdown":"https://secwatch.observer/filing/0001193125-26-267487.md","text":"https://secwatch.observer/filing/0001193125-26-267487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526267487/0001193125-26-267487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526267487/bolt-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:11:59.794997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a91ef111d99f0a35994da8742f89e1de5113073e","claim":"Bolt Biotherapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-10 meeting.","evidence_excerpt":"The following director nominees were elected to serve as Class II members of the Company’s board of directors until the Company’s 2029 Annual Meeting of Stockholders, or until their respective successor is duly elected and qualified, or until their respective death, resignation or removal:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526267487/0001193125-26-267487-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"b97ed642f1cf9f153ad7a55474a9132dc19d4fe3","claim":"Bolt Biotherapeutics, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 at the 2026-06-10 meeting.","evidence_excerpt":"The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526267487/0001193125-26-267487-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}